Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model
Authors:
Open Access
- 3 August 2026
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (5) , 847-857
Abstract
No abstract availableKeywords
Funding Information
- Roche Italia
This publication has 33 references indexed in Scilit:
- Personalized therapy in multiple sclerosis: an Italian Delphi consensusJournal of Neurology, 2025
- Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionalsJournal of Neurology, 2024
- Identification of the most cost-saving disease-modifying therapies and factors affecting the budget in the pharmacotherapy of multiple sclerosis: a systematic reviewEuropean Journal of Clinical Pharmacology, 2024
- Intravenous or subcutaneous natalizumab in patients with relapsing–remitting multiple sclerosis: investigation on efficiency and savings—the EASIER studyJournal of Neurology, 2023
- Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world dataMultiple Sclerosis and Related Disorders, 2023
- Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in PortugalPharmacoEconomics - Open, 2022
- Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in CanadaPharmacoEconomics - Open, 2022
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM StudyJAMA Neurology, 2021
- The Economic Burden of Different Multiple Sclerosis PhenotypesValue in Health, 2017
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialThe Lancet, 2012